Department of Biotechnology, National Institute of Technology Durgapur, Durgapur, 713209, India.
Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
BMC Bioinformatics. 2022 Aug 5;23(1):319. doi: 10.1186/s12859-022-04816-6.
Visceral Leishmaniasis (VL) is a fatal vector-borne parasitic disorder occurring mainly in tropical and subtropical regions. VL falls under the category of neglected tropical diseases with growing drug resistance and lacking a licensed vaccine. Conventional vaccine synthesis techniques are often very laborious and challenging. With the advancement of bioinformatics and its application in immunology, it is now more convenient to design multi-epitope vaccines comprising predicted immuno-dominant epitopes of multiple antigenic proteins. We have chosen four antigenic proteins of Leishmania donovani and identified their T-cell and B-cell epitopes, utilizing those for in-silico chimeric vaccine designing. The various physicochemical characteristics of the vaccine have been explored and the tertiary structure of the chimeric construct is predicted to perform docking studies and molecular dynamics simulations.
The vaccine construct is generated by joining the epitopes with specific linkers. The predicted tertiary structure of the vaccine has been found to be valid and docking studies reveal the construct shows a high affinity towards the TLR-4 receptor. Population coverage analysis shows the vaccine can be effective on the majority of the world population. In-silico immune simulation studies confirms the vaccine to raise a pro-inflammatory response with the proliferation of activated T and B cells. In-silico codon optimization and cloning of the vaccine nucleic acid sequence have also been achieved in the pET28a vector.
The above bioinformatics data support that the construct may act as a potential vaccine. Further wet lab synthesis of the vaccine and in vivo works has to be undertaken in animal model to confirm vaccine potency.
内脏利什曼病(VL)是一种主要发生在热带和亚热带地区的致命寄生虫病。VL 属于被忽视的热带病,具有耐药性不断增加和缺乏许可疫苗的特点。传统的疫苗合成技术通常非常繁琐和具有挑战性。随着生物信息学的进步及其在免疫学中的应用,现在更方便设计包含多个抗原蛋白预测免疫显性表位的多表位疫苗。我们选择了利什曼原虫的四个抗原蛋白,并利用这些蛋白进行了 T 细胞和 B 细胞表位的预测,以便进行计算机模拟嵌合疫苗设计。我们还探索了疫苗的各种物理化学特性,并预测了嵌合构建体的三级结构,以进行对接研究和分子动力学模拟。
通过使用特定的接头将表位连接起来,生成疫苗构建体。预测的疫苗三级结构被证明是有效的,对接研究表明该构建体与 TLR-4 受体具有高亲和力。人群覆盖率分析表明,该疫苗可以对世界上大多数人口有效。计算机模拟免疫研究证实,该疫苗可以引发促炎反应,促进激活的 T 和 B 细胞的增殖。还在 pET28a 载体中实现了疫苗核酸序列的计算机模拟密码子优化和克隆。
上述生物信息学数据支持该构建体可能作为一种潜在的疫苗。需要在动物模型中进行疫苗的实际合成和体内试验,以确认疫苗的效力。